Mentioned:
Hims & Hers Health wants in on the opportunity in peptides. And now, Andrew Huberman is joining them.
What’s happening:
- Neuroscientist and Stanford professor Andrew Huberman has officially joined the board of directors of Hims & Hers Health (NYSE: HIMS)
Why it matters:
- Andrew Huberman hosts one the most popular health and science podcasts in the world and has more than 8M YouTube subscribers
Going deeper:
- Hims & Hers Health has publicly stated that they will collaborate with Andrew Humberman closely on shaping the clinical standards and testing for their new Peptides+ offering
- Andrew Huberman will also provide marketing for Hims & Hers Health on his podcast and YouTube channel through an advisory and advertising deal
The fine print:
- Hims & Hers Health’s Peptide+ product line is a set of compounded wellness peptides starting with sermorelin, NAD+ and glutathione that have not yet been approved by the United States Food and Drug Administration
